The trading social network: Get information, share to succeed in the market

0.300 +1.70% > News

PR Newswire published a news.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mesoblast Limited of Class Action Law Suit and Upcoming Deadline - MESO • • PR Newswire • Stocks

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mesoblast Limited of Class Action Law Suit and Upcoming Deadline - MESO PR Newswire NEW YORK, Dec. 5, 2020 NEW YORK , Dec. 5, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO) and certain of its officers. The class action, filed in United States District Court for the Southern District of New...

Thank you Chart

3.73 +2.47% > News

Business Wire published a news.

GlycoMimetics’ Uproleselan in Combination With Venetoclax/HMA Shown to Break Chemoresistance, Reduce Tumor Burden and Increase Survival in AML Model • • Business Wire • Stocks

GlycoMimetics’ (Nasdaq: GLYC) product candidate uproleselan — when added to a combination therapy of venetoclax and a hypomethylating agent (HMA) — was shown today in an oral presentation to break chemoresistance by dramatically and significantly reducing tumor burden as detected by circulating human AML cells after three weeks of treatment, and by significantly increasing survival ( p = 0.0009) in an animal model engrafted with AML from a patient with acquired resistance to venetoclax/HMA...

Thank you Chart

DREAM > News

NBC News posted a new video.

John Leguizamo On The Lack Of Latino Roles In Hollywood And His American Dream | NBC Nightly News • • NBC News • Cryptocurrencies

Watch live coverage as President Trump holds a rally in Georgia to campaign for the Republican candidates running in the state's Senate runoff election....

Thank you

492.45 -1.28% > News

PR Newswire published a news.

Regeneron's BCMAxCD3 Bispecific Antibody (REGN5458) Shows Deep and Durable Responses in Patients with Heavily-pretreated Multiple Myeloma in Phase 1 • • PR Newswire • Stocks

Regeneron's BCMAxCD3 Bispecific Antibody (REGN5458) Shows Deep and Durable Responses in Patients with Heavily-pretreated Multiple Myeloma in Phase 1 PR Newswire TARRYTOWN, N.Y., Dec. 5, 2020 TARRYTOWN, N.Y. , Dec. 5, 2020 /PRNewswire/ -- 63% response rate in patients treated with the highest reported dose Among all patients responding to treatment, 95% experienced a very good partial response or better; among responding patients with ≥6 months of follow-up, 83% have ongoing responses for up to...

Thank you Chart

News

RT posted a new video.

Global Economic Machine • • RT • Economy

On the show this week, Chris Hedges talks to Fabian Scheidler about how the global economic machine came to dominate our lives, and with looming social ......

Thank you

23.85 +3.70% > News

GlobeNewsWire published a news.

Cellectis Reports Preliminary Results from its Phase 1 BALLI-01 Study of UCART22 in R/R Adult B-ALL at American Society of Hematology (ASH) Annual Meeting • • GlobeNewsWire • Stocks

Cellectis’ Proprietary Program UCART22 was Safely Administered in BALLI-01 Phase 1 Study with No Dose-Limiting Toxicity or Evidence of Graft-Vs-Host Disease 2 out of 3 Patients at DL1 Achieved CR/CRi and 1 out of 2 Patients at DL2 Achieved a Significant Reduction in Bone Marrow Blasts BALLI-01 Currently Enrolling at DL2 with Addition of Alemtuzumab to the FC Lymphodepletion Regimen; Next Data Update Expected in 2021 NEW YORK, Dec. 05, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS...

Thank you Chart

19,258.19 +0.54% > News

Crypto Daily posted a new video.

Why THIS Is Now An Inevitability for Bitcoin • • Crypto Daily • Cryptocurrencies

...

Thank you Chart

MAN > News

Euronews posted a new video.

Man charged with deadly 1982 attack on kosher restaurant in Paris • • Euronews • Stocks

Walid Abdulrahman Abou Zayed was extradited to France on Friday by Norway, where he had settled in 1991. READ MORE ......

Thank you

6.02 +3.44% > News

Business Wire published a news.

ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting • • Business Wire • Stocks

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that new safety and efficacy findings from the expansion phase of the Phase 1/2 study of IMGN632 in patients with relapsed/refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) were presented during an oral session at the 62 nd American Society of Hematology (ASH) Annual Meeting. “Comprising the largest prospective study with a single agent in...

Thank you Chart

16.90 +3.62% > News

Business Wire published a news.

Long-Term Data for bluebird bio’s betibeglogene autotemcel (beti-cel) Gene Therapy Show Patients Across Ages and β-thalassemia Genotypes Achieve Transfusion Independence and Remain Free from Transfusions Up to Six Years Presented at 62nd ASH Meeting • • Business Wire • Stocks

bluebird bio, Inc. (Nasdaq: BLUE) today presented updated long-term efficacy and safety results reflecting up to six years of data for betibeglogene autotemcel gene therapy (beti-cel; formerly LentiGlobin™ for β-thalassemia) in patients with transfusion-dependent β-thalassemia (TDT). The company also presented results for pediatric patients in the Phase 3 HGB-207 (Northstar-2) and HGB-212 (Northstar-3) studies. These data were presented at the 62 nd American Society of Hematology (ASH)...

Thank you Chart

News

Business Wire published a news.

Legend Biotech Announces Phase 1b/2 Study Data of Cilta-cel, an Investigational BCMA CAR-T, Showing Early, Deep, and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma • • Business Wire • Stocks

Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced the latest data results from the combined Phase 1b/2 CARTITUDE-1 study ( NCT03548207 ) of ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA) directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of...

Thank you

229.21 +1.01% > News

PR Newswire published a news.

Amgen To Present First Clinical Data For BCMA-Targeted Half-Life Extended BiTE® Therapy AMG 701 At ASH 2020 • • PR Newswire • Stocks

Amgen To Present First Clinical Data For BCMA-Targeted Half-Life Extended BiTE® Therapy AMG 701 At ASH 2020 83% Overall Response Rate in Most Recent Evaluable Cohort of Heavily Pre-Treated Multiple Myeloma Patients Data Show Encouraging Activity With Responses Lasting up to 26 Months PR Newswire THOUSAND OAKS, Calif., Dec. 5, 2020 THOUSAND OAKS, Calif. , Dec. 5, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the first presentation of clinical safety and efficacy data from the Phase 1...

Thank you Chart

10.50 -0.57% > News

GlobeNewsWire published a news.

Autolus Therapeutics presents compelling AUTO1 data from ALLCAR Phase 1 study in Adult Acute Lymphoblastic Leukemia (ALL) during the 62nd ASH Annual Meeting • • GlobeNewsWire • Stocks

Updated data from the ALLCAR study suggests AUTO1’s potential for transformational activity in adult patients with r/r ALL Conference call and webcast to be held Monday, December 7, 2020 at 4:00 pm ET / 9:00 pm GMT LONDON, Dec. 05, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced new data highlighting progress on its AUTO1 program, the company’s CAR T cell...

Thank you Chart

News

Chico Crypto posted a new video.

Incoming Airdrops BIGGER than Uniswap!! 1 Right NOW! 2 Soon!! • • Chico Crypto • Cryptocurrencies

Get your FREE crypto! We've identified 3 Airdrops bigger than the Uniswap UNI Airdrop!! Including one you can claim right NOW!! Worth more than a brand new ......

Thank you

586.5 +0.00% > News

Business Wire published a news.

ROSEN, TRUSTED INVESTOR COUNSEL, Reminds Intercept Pharmaceuticals, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – ICPT • • Business Wire • Stocks

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between September 28, 2019 and October 7, 2020, inclusive (the “Class Period”), of the important January 4, 2021 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Intercept investors under the federal securities laws. To join the Intercept class action, go to http://www.rosenlegal.com/cases-register-1973.html...

Thank you Chart

Load more content

My lists

NASDAQ COMPOSITE INDEX	12,464.23	+0.70%
DAX30 PERF INDEX	13,298.96	+0.35%
CAC40 INDEX	5,609.15	+0.62%
ESTOXX50 PRICE EUR INDEX	3,539.27	+0.63%
EUR/USD	1.2122	-0.19%
GBP/USD	1.3439	-0.10%
SILVER - USD	24.19	+0.62%
GOLD - USD	1,838.62	-0.07%
BITCOIN - BTC/USD	19,260.08	+0.55%
ETHEREUM - ETH/USD	604.04	+1.22%
RIPPLE - XRP/USD	0.608600	+3.96%

Technical analysis requests

scoxino BITCOIN - BTC/USD - 1H
chemichi777 BITCOIN - BTC/USD - 15 min.
chemichi777 BITCOIN - BTC/USD - 15 min.

See all analysis requests

Top / Flop

BILIBILI INC. ADS	67.79	+8.76%
LYFT INC.	46.10	+6.96%
WESTERN DIGITAL	51.75	+6.75%
RYANAIR HOLDINGS PLC ADS	116.31	+6.13%
DOCUSIGN INC.	243.22	+5.29%
TAKE-TWO INTERACTIVE SOFTWARE	180.73	-0.02%
BAIDU INC. ADS	144.07	-0.12%
SOLAREDGE TECHNOLOGIES INC.	271.97	-0.13%
COSTCO WHOLESALE	373.43	-0.17%
MERCADOLIBRE INC.	1,557.38	-0.19%

See all Top/Flop list

Market scanning tools

See all Signals

Instruments' Ranking

Sorry, there is no result for this selection

Trader Ranking

Sorry, there is no result for this selection

Traders' nationalities

546 traders
- 76530
99 traders
- 17210
65 traders
- 10611
20 traders
- 10517
51 traders
- 10332
11 traders
- 8648

Timeframe rankings

4H
- 8
Monthly
- 3
10 min.
- 2
2H
- 2
8H
- 2
30 min.
- 1